We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.
- Authors
Rubenstein, J L; Kim, J; Ozawa, T; Zhang, M; Westphal, M; Deen, D F; Shuman, M A
- Abstract
Vascular endothelial growth factor (VEGF) is an important mediator of the intense angiogenesis which is characteristic of glioblastoma. While genetic manipulation of VEGF/VEGF receptor expression has previously been shown to inhibit glioblastoma growth, to date, no study has examined the efficacy of pharmacologic blockade of VEGF activity as a means to inhibit intracranial growth of human glioblastoma. Using intraperitoneal administration of a neutralizing anti-VEGF antibody, we demonstrate that inhibition of VEGF significantly prolongs survival in athymic rats inoculated in the basal ganglia with G55 human glioblastoma cells. Systemic anti-VEGF inhibition causes decreased tumor vascularity as well as a marked increase in tumor cell apoptosis in intracranial tumors. Although intracranial glioblastoma tumors grow more slowly as a consequence of anti-VEGF treatment, the histologic pattern of growth suggests that these tumors adapt to inhibition of angiogenesis by increased infiltration and cooption of the host vasculature.
- Publication
Neoplasia (New York, N.Y.), 2000, Vol 2, Issue 4, p306
- ISSN
1522-8002
- Publication type
Journal Article
- DOI
10.1038/sj.neo.7900102